Patents by Inventor Clive L. Jennings-White

Clive L. Jennings-White has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 17-methylenandrostan-3alpha-ol analogs as CRH inhibitors
    Publication number: 20030220309
    Abstract: 17-Methylenandrostan-3&agr;-ol analogs are useful as corticotropin releasing hormone (CRH) inhibitors, and especially as anti-depressants, when administered to the vomeronasal organ. An improved synthesis of 17-methylenandrost-4-en-3&agr;-ol is disclosed.
    Type: Application
    Filed: June 13, 2003
    Publication date: November 27, 2003
    Applicant: Pherin Pharmaceuticals, Inc.
    Inventors: Louis Monti, David L. Berliner, Clive L. Jennings-White, Nathan W. Adams
  • Weight promoting composition, method, and product
    Patent number: 6555531
    Abstract: Pregnanes of formula I, and pharmaceutical compositions and products containing them, are useful in weight promotion by administration to the vomeronasal organ.
    Type: Grant
    Filed: December 30, 1999
    Date of Patent: April 29, 2003
    Assignee: Pherin Pharmaceuticals, Inc.
    Inventors: David L. Berliner, Louis Monti, Clive L. Jennings-White
  • Method of increasing alertness by administration of a vomeropherin, and vomeropherin-emitting alarm devices
    Patent number: 6544971
    Abstract: A method of increasing alertness in an individual by administering an effective amount of an alertness-increasing vomeropherin to the individual; and an alarm device that, when activated, emits an alertness-increasing vomeropherin. The method and device are especially useful in increasing alertness in individuals who are not readily responsive to usual external stimuli.
    Type: Grant
    Filed: February 4, 2000
    Date of Patent: April 8, 2003
    Assignee: Pherin Pharmaceuticals, Inc.
    Inventors: David L. Berliner, Louis Monti, Clive L. Jennings-White
  • 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors
    Publication number: 20030045514
    Abstract: 17-Methyleneandrostan-3&agr;-ol analogs are useful as corticotropin releasing hormone (CRH) inhibitors, and especially as anti-depressants, when administered to the vomeronasal organ. An improved synthesis of 17-methylenandrost-4-en-3&agr;-ol is disclosed.
    Type: Application
    Filed: May 3, 2001
    Publication date: March 6, 2003
    Inventors: Louis Monti, David L. Berliner, Clive L. Jennings-White, Nathan W. Adams
  • Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
    Publication number: 20020143001
    Abstract: The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e.g. an Androstane steroid, or a pharmaceutical composition containing a semiochemical, such that the ligand semiochemical binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.
    Type: Application
    Filed: August 3, 2001
    Publication date: October 3, 2002
    Inventors: David L. Berliner, Nathan William Adams, Clive L. Jennings-White
  • 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function
    Patent number: 6437156
    Abstract: The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human vomeropherin, e.g. a 19-nor cholane steroid, or a pharmaceutical composition containing a vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.
    Type: Grant
    Filed: February 2, 1999
    Date of Patent: August 20, 2002
    Assignee: Pherin Corporation
    Inventors: Clive L. Jennings-White, David L. Berliner, Nathan W. Adams
  • 19-nor-cholane steroids as neurochemical initators of change in human hypothalamic function
    Patent number: 6432938
    Abstract: The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human vomeropherin, e.g. a 19-nor cholane steroid, or a pharmaceutical composition containing a vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.
    Type: Grant
    Filed: June 9, 1997
    Date of Patent: August 13, 2002
    Assignee: Pherin Corporation
    Inventors: Clive L. Jennings-White, David L. Berliner, Nathan W. Adams
  • Novel androstanes for inducing hypothalamic effects
    Publication number: 20020103391
    Abstract: The invention relates to novel, androstane steroids which are the ligand semiochemicals which bind to neuroepithelial receptors.
    Type: Application
    Filed: March 9, 2001
    Publication date: August 1, 2002
    Inventors: David L. Berliner, Nathan W. Adams, Clive L. Jennings-White
  • Estrenes for inducting hypothalamic effects
    Patent number: 6352980
    Abstract: The invention relates to estrene steroids, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.
    Type: Grant
    Filed: September 21, 1999
    Date of Patent: March 5, 2002
    Assignee: Pherin Pharmaceuticals, Inc.
    Inventors: David L. Berliner, Nathan W. Adams, Clive L. Jennings-White
  • 19-norpregnane steroids as neurochemical initiators of change in human hypothalamic function
    Patent number: 6242619
    Abstract: Several 19-nor-pregnanes are provided which have the capacity to neurochemically alter the hypothalamic function in an individual through nasal administration. These pharmaceutically active compounds can be administered by themselves or in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers to produce the desired effect.
    Type: Grant
    Filed: August 11, 1998
    Date of Patent: June 5, 2001
    Assignee: Pherin Pharmaceuticals, Inc.
    Inventors: Clive L. Jennings-White, David L. Berliner, Nathan W. Adams
  • Estrene steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions
    Patent number: 6140316
    Abstract: The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e.g. an Estrene steroid, or a pharmaceutical composition containing an Estrene steroid, such that the ligand semiochemical binds to a specific neuroepithelial receptor. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.
    Type: Grant
    Filed: July 21, 1998
    Date of Patent: October 31, 2000
    Assignee: Pherin Corporation
    Inventors: David L. Berliner, Nathan William Adams, Clive L. Jennings-White
  • Steroids as neurochemical stimulators of the VNO to treat paroxistic tachycardia
    Patent number: 6117860
    Abstract: The invention relates to a method of alleviating the symptoms of PMS and anxiety. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.
    Type: Grant
    Filed: July 23, 1997
    Date of Patent: September 12, 2000
    Assignee: Pherin Pharmaceuticals, Inc.
    Inventors: Clive L. Jennings-White, David L. Berliner, Nathan W. Adams, Luis Monti-Bloch
  • Steroids as neurochemical initiators of change in human blood levels of LH
    Patent number: 6066627
    Abstract: The invention relates to a method of altering the blood levels of LH or FSH in an individual. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.
    Type: Grant
    Filed: March 29, 1996
    Date of Patent: May 23, 2000
    Assignee: Pherin Corporation
    Inventors: Clive L. Jennings-White, David L. Berliner, Nathan W. Adams
  • Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety
    Patent number: 6057439
    Abstract: The invention relates to a method of alleviating the symptoms of PMS and anxiety. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.
    Type: Grant
    Filed: July 23, 1996
    Date of Patent: May 2, 2000
    Assignee: Pherin Corporation
    Inventors: Clive L. Jennings-White, David L. Berliner, Nathan W. Adams, Luis Monti-Bloch
  • Pregnane and cholane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
    Patent number: 5994333
    Abstract: The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human vomeropherin, e.g. a pregnane or cholane steroid, or a pharmaceutical composition containing a vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.
    Type: Grant
    Filed: August 3, 1995
    Date of Patent: November 30, 1999
    Assignee: Pherin Corporation
    Inventors: Clive L. Jennings-White, David L. Berliner, Nathan William Adams
  • Estrenes for inducing hypothalamic effects
    Patent number: 5994568
    Abstract: The invention relates to estrene steroids, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 30, 1999
    Assignee: Pherin Corporation
    Inventors: David L. Berliner, Nathan W. Adams, Clive L. Jennings-White
  • Androstanes for inducing hypothalamic effects
    Patent number: 5969168
    Abstract: The invention relates to novel, androstane steroids which are the ligand semiochemicals which bind to neuroepithelial receptors. The steroids are useful as ligands to neuroepithelial receptors in the human vomeronasal gland to stimulate autonomic and hypothalamic activity.
    Type: Grant
    Filed: September 29, 1994
    Date of Patent: October 19, 1999
    Assignee: Pherin Corporation
    Inventors: David L. Berliner, Nathan W. Adams, Clive L. Jennings-White
  • Androstane steroids as neurochemical initators of change in human hypothalamic compositions and methods
    Patent number: 5965552
    Abstract: The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e.g. an Androstane steroid, or a pharmaceutical composition containing a semiochemical, such that the ligand semiochemical binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.
    Type: Grant
    Filed: December 15, 1998
    Date of Patent: October 12, 1999
    Assignee: Pherin Pharmaceuticals, Inc.
    Inventors: David L. Berliner, Nathan William Adams, Clive L. Jennings-White
  • 19-nur-pregnane steroids as neurochemical initiators of change in human hypothalamic function
    Patent number: 5962443
    Abstract: The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human vomeropherin, e.g. a 19-nor pregnane steroid, or a pharmaceutical composition containing a vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: October 5, 1999
    Assignee: Pherin Corporation
    Inventors: Clive L. Jennings-White, David L. Berliner, Nathan W. Adams
  • Estrenes for inducing hypothalamic effects
    Patent number: 5939570
    Abstract: The invention relates to estrene steroids, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.
    Type: Grant
    Filed: June 4, 1997
    Date of Patent: August 17, 1999
    Assignee: Pherin Corporation
    Inventors: David L. Berliner, Nathan W. Adams, Clive L. Jennings-White